Probe Cocktail Studies

Chapter
Part of the Infectious Disease book series (ID)

Abstract

The conduct of drug interaction studies was revolutionized by the ability to evaluate more than one potential drug-drug interaction (DDI) within a single study. Cocktail studies provide a means to screen for DDIs through multiple metabolic pathways within a single study. Usually conducted in healthy volunteers, these studies use concurrent administration of probe substrates and assessment of biomarkers to simultaneously assess drug-metabolizing enzyme (DME) activities before (baseline) and during drug treatment. Evaluation of DME can be for effect of a drug on constitutive DME (i.e., inhibition, induction, or activation) or to evaluate the effect of an inhibitor, inducer, or activator on the pharmacokinetics and pharmacodynamics of the DME pathway of the drug in question. Studies should be designed with the use of safe, validated probes and published, validated cocktails. Advantages of using cocktail studies in drug development include reduced subject variability (because the same subjects are used for each phase of the study), increased efficiency, and lower costs. Potential limitations can be addressed by proper study design. Because cocktail studies assess the potential extent of DDIs, inferences for drug dosing and use may be drawn.

Keywords

Variability Optimal design Validated probes Midazolam Dextromethorphan Caffeine Omeprazole Warfarin Rosiglitazone Bupropion 

References

  1. 1.
    In vivo drug metabolism/drug interaction studies – study design, data analysis, and recommendations for dosing and labeling. Food and Drug Administration, Rockville, 1999Google Scholar
  2. 2.
    Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81(2):270–283Google Scholar
  3. 3.
    Zhou H, Sharma A (2016) Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies. Expert Opin Drug Metab Toxicol 12(11):1–9Google Scholar
  4. 4.
    Zhou H, Tong Z, McLeod JF (2004) “Cocktail” approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44(2):120–134PubMedGoogle Scholar
  5. 5.
    Ebner T, Ishiguro N, Taub ME (2015) The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. J Pharm Sci 104(9):3220–3228PubMedGoogle Scholar
  6. 6.
    Ma JD, Tsunoda SM, Bertino JS Jr, Trivedi M, Beale KK, Nafziger AN (2010) Evaluation of in vivo p-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet 49(4):223–237PubMedGoogle Scholar
  7. 7.
    Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME et al (2016) Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther 100(3):259–267PubMedPubMedCentralGoogle Scholar
  8. 8.
    Baker SD, van Schaik RH, Rivory LP, Ten Tije AJ, Dinh K, Graveland WJ et al (2004) Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 10(24):8341–8350PubMedGoogle Scholar
  9. 9.
    Frye RF, Zgheib NK, Matzke GR, Chaves-Gnecco D, Rabinovitz M, Shaikh OS et al (2006) Liver disease selectively modulates cytochrome P450--mediated metabolism. Clin Pharmacol Ther 80(3):235–245PubMedGoogle Scholar
  10. 10.
    Frye RF, Schneider VM, Frye CS, Feldman AM (2002) Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 8(5):315–319PubMedPubMedCentralGoogle Scholar
  11. 11.
    McConn DJ, Lin YS, Mathisen TL, Blough DK, Xu Y, Hashizume T et al (2009) Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. Clin Pharmacol Ther 85(4):387–393PubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee CM, Pohl J, Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 37(4):865–872PubMedPubMedCentralGoogle Scholar
  13. 13.
    Jones AE, Brown KC, Werner RE, Gotzkowsky K, Gaedigk A, Blake M et al (2010) Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 66:475PubMedPubMedCentralGoogle Scholar
  14. 14.
    Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O et al (2003) Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 304(2):745–752PubMedGoogle Scholar
  15. 15.
    He P, Court MH, Greenblatt DJ, Von Moltke LL (2005) Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77(5):373–387PubMedGoogle Scholar
  16. 16.
    Saari TI, Laine K, Neuvonen M, Neuvonen PJ, Olkkola KT (2008) Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 64(1):25–30PubMedGoogle Scholar
  17. 17.
    Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS et al (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79(3):243–254PubMedGoogle Scholar
  18. 18.
    Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC et al (2009) Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos 37(3):514–522PubMedGoogle Scholar
  19. 19.
    Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9(4):310–322PubMedGoogle Scholar
  20. 20.
    Lammers LA, Achterbergh R, de Vries EM, van Nierop FS, Klumpen HJ, Soeters MR et al (2015) Short-term fasting alters cytochrome P450-mediated drug metabolism in humans. Drug Metab Dispos 43(6):819–828PubMedGoogle Scholar
  21. 21.
    Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C et al (2007) Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81(4):510–516PubMedGoogle Scholar
  22. 22.
    Tracy TS, Venkataramanan R, Glover DD, Caritis SN (2005) Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol 192(2):633–639PubMedGoogle Scholar
  23. 23.
    Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J (2006) Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17(9):2363–2367PubMedGoogle Scholar
  24. 24.
    Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR et al (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36(2):205–216PubMedPubMedCentralGoogle Scholar
  25. 25.
    Bosilkovska M, Samer CF, Deglon J, Rebsamen M, Staub C, Dayer P et al (2014) Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther 96(3):349–359PubMedPubMedCentralGoogle Scholar
  26. 26.
    Zgheib NK, Frye RF, Tracy TS, Romkes M, Branch RA (2006) Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clin Pharmacol Ther 80(3):257–263PubMedGoogle Scholar
  27. 27.
    Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10(5):373–388PubMedGoogle Scholar
  28. 28.
    Schellens JH, van der Wart JH, Brugman M, Breimer DD (1989) Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a “cocktail” study design. J Pharmacol Exp Ther 249(2):638–645PubMedGoogle Scholar
  29. 29.
    Lesko LJ, Lagishetty CV (2016) Are we getting the best return on investment from clinical drug-drug interaction studies? J Clin Pharmacol 56(5):555–558PubMedGoogle Scholar
  30. 30.
    Zhang L (2010) A regulatory perspective on the utilization of cocktail approach in assessing drug interactions. FIP Pharmaceutical Sciences World Congress – American Association of Pharmaceutical Scientists Annual meeting, New Orleans, 16 November 2010Google Scholar
  31. 31.
    Ryu JY, Song IS, Sunwoo YE, Shon JH, Liu KH, Cha IJ et al (2007) Development of the “Inje cocktail” for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82(5):531–540PubMedGoogle Scholar
  32. 32.
    Rezk NL, Brown KC, Kashuba AD (2006) A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure. J Chromatogr B Analyt Technol Biomed Life Sci 844(2):314–321PubMedGoogle Scholar
  33. 33.
    Liu Y, Jiao J, Zhang C, Lou J (2009) A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. Biol Pharm Bull 32(4):717–720PubMedGoogle Scholar
  34. 34.
    CHMP Efficacy Working Party Therapeutic Subgroup on Pharmacokinetics. London: European Medicines Agency; 2009 22 January. Contract No.: EMEA/618604/2008Google Scholar
  35. 35.
    Drug interaction studies —study design, data analysis, implications for dosing, and labeling recommendations In: Pharmacology C (ed) US Food and Drug Administration, Silver Spring, MD, 2012, pp 1–79Google Scholar
  36. 36.
    Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–832PubMedGoogle Scholar
  37. 37.
    Tucker GT, Houston JB, Huang SM (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential – toward a consensus. Pharm Res 18(8):1071–1080PubMedGoogle Scholar
  38. 38.
    Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81(2):298–304PubMedGoogle Scholar
  39. 39.
    Bertino JS Jr, Nafziger AN (2007) Labeling of drug interactions. Is change needed? Clin Pharmacol Ther 81(Suppl):S90Google Scholar
  40. 40.
    Liu X, Jia L (2007) The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies. Curr Drug Metab 8(8):815–821PubMedPubMedCentralGoogle Scholar
  41. 41.
    Bjornsson T, Callaghan J, Einolf H, Fischer V, Gan L, Grimm S et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–469PubMedGoogle Scholar
  42. 42.
    Jia L, Liu X (2007) The conduct of drug metabolism studies considered good practice (II): in vitro experiments. Curr Drug Metab 8(8):822–829PubMedPubMedCentralGoogle Scholar
  43. 43.
    Venkatakrishnan K, von Moltke LL, Obach RS, Greenblatt DJ (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr Drug Metab 4(5):423–459PubMedGoogle Scholar
  44. 44.
    Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825–833PubMedGoogle Scholar
  45. 45.
    Krosser S, Neugebauer R, Dolgos H, Fluck M, Rost KL, Kovar A (2006) Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. Eur J Clin Pharmacol 62(4):277–284PubMedGoogle Scholar
  46. 46.
    Rostami-Hodjegan A, Tucker G (2004) ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions. Drug Discov Today Technol 1(4):441–448PubMedGoogle Scholar
  47. 47.
    Drug interaction studies-study design, data analysis, and implications for dosing and labeling. U.S. Food and Drug Administration, Rockville, 2006Google Scholar
  48. 48.
    Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E et al (1999) FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 39(9):899–910PubMedGoogle Scholar
  49. 49.
    Weaver RJ (2001) Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 31(8-9):499–538PubMedGoogle Scholar
  50. 50.
    Lu C, Hatsis P, Berg C, Lee FW, Balani SK (2008) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole. Drug Metab Dispos 36(7):1255–1260PubMedGoogle Scholar
  51. 51.
    Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK (2007) A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 35(1):79–85PubMedGoogle Scholar
  52. 52.
    Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH et al (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 37(7):1355–1370PubMedGoogle Scholar
  53. 53.
    Drug development and drug interactions: table of substrates, inhibitors and inducers. US Food and Drug Administration, 2015Google Scholar
  54. 54.
    Table 2-1: Examples of clinical index substrates for P450-mediated metabolism (for use in index clinical DDI studies) (9/26/2016): US Food and Drug Administration; 2016 [updated 26 September 2016. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm – table2-1
  55. 55.
    Watkins P (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171–184PubMedGoogle Scholar
  56. 56.
    Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63(4):321–333PubMedGoogle Scholar
  57. 57.
    Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC (2005) Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 33(7):1052–1055PubMedGoogle Scholar
  58. 58.
    Ozdemir M, Crewe KH, Tucker GT, Rostami-Hodjegan A (2004) Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol 44(12):1398–1404PubMedGoogle Scholar
  59. 59.
    Labbe L, Sirois C, Pilote S, Arseneault M, Robitaille NM, Turgeon J et al (2000) Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 10(5):425–438PubMedGoogle Scholar
  60. 60.
    Bioavailability and bioequivalence requirements; Abbreviated applications; Final Rule. In: Food and Drug Administration H (ed), U.S. Department of Health and Human Services, 2002, pp 77668–77675Google Scholar
  61. 61.
    Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE et al (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271(1):557–566PubMedGoogle Scholar
  62. 62.
    Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS et al (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 271(1):549–556PubMedGoogle Scholar
  63. 63.
    Streetman DS, Kashuba AD, Bertino JS Jr, Kulawy R, Rocci ML Jr, Nafziger AN (2001) Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. Pharmacogenetics 11(4):349–355PubMedGoogle Scholar
  64. 64.
    Lee LS, Bertino JS Jr, Nafziger AN (2006) Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol 46(2):229–234PubMedGoogle Scholar
  65. 65.
    Ma JD, Nafziger AN, Kashuba AD, Kim MJ, Gaedigk A, Rowland E et al (2004) Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers. J Clin Pharmacol 44(6):570–576PubMedGoogle Scholar
  66. 66.
    Rogers JF, Nafziger AN, Kashuba AD, Streetman DS, Rocci ML Jr, Choo EF et al (2002) Single plasma concentrations of 1′-hydroxymidazolam or the ratio of 1′-hydroxymidazolam:midazolam do not predict midazolam clearance in healthy subjects. J Clin Pharmacol 42(10):1079–1082PubMedGoogle Scholar
  67. 67.
    Guideline on the investigation of drug interactions. In: Products CfHM, editor. CPMP/EWP/560/95/Rev. 1 Corr. 2 ed. European Medicines Agency, London, 2012, pp 1–59Google Scholar
  68. 68.
    Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4(3):109–116PubMedGoogle Scholar
  69. 69.
    Johnson BM, Song IH, Adkison KK, Borland J, Fang L, Lou Y et al (2006) Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail. J Clin Pharmacol 46(5):577–587PubMedGoogle Scholar
  70. 70.
    Sarkar MA, Jackson BJ (1994) Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 22(6):827–834PubMedGoogle Scholar
  71. 71.
    Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ (2004) Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76(6):598–606PubMedGoogle Scholar
  72. 72.
    Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM et al (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28(10):1222–1230PubMedGoogle Scholar
  73. 73.
    Kharasch ED, Mitchell D, Coles R (2008) Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 48(4):464–474PubMedGoogle Scholar
  74. 74.
    Totah RA, Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77(5):341–352PubMedGoogle Scholar
  75. 75.
    Niemi M, Backman JT, Neuvonen PJ (2004) Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 76(3):239–249PubMedGoogle Scholar
  76. 76.
    Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56(3):305–314PubMedPubMedCentralGoogle Scholar
  77. 77.
    Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS (2006) CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. Drug Metab Dispos 34(12):1966–1975PubMedGoogle Scholar
  78. 78.
    Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J et al (2004) Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60(3):165–171PubMedGoogle Scholar
  79. 79.
    Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26(6):753–759PubMedGoogle Scholar
  80. 80.
    Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9(5):539–549PubMedGoogle Scholar
  81. 81.
    Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R et al (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole – suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39(5):511–518PubMedPubMedCentralGoogle Scholar
  82. 82.
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353(1):16–28PubMedGoogle Scholar
  83. 83.
    Karam WG, Goldstein JA, Lasker JM, Ghanayem BI (1996) Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 24(10):1081–1087PubMedGoogle Scholar
  84. 84.
    Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T et al (2004) Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol 60(9):623–628PubMedGoogle Scholar
  85. 85.
    Thacker DL, Modak AS, Lemler SM, Flockhart DA, Desta Z (2010) Cytochrome P450 (CYP) 2C19 specific breath test using (+)-[13C]-pantoprazole as a phenotype probe. Clin Pharmacol Ther 87(Suppl 1):S51Google Scholar
  86. 86.
    Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L et al (2009) Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test. J Pharmacol Exp Ther 329(1):297–305PubMedPubMedCentralGoogle Scholar
  87. 87.
    Streetman D, Bertino J Jr, Nafziger A (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216PubMedGoogle Scholar
  88. 88.
    Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E (1997) Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. Br J Clin Pharmacol 43(3):315–318PubMedPubMedCentralGoogle Scholar
  89. 89.
    Lindamood C, Ortiz S, Shaw A, Rackley R, Gorski JC (2011) Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 51(4):575–585PubMedGoogle Scholar
  90. 90.
    Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA (1998) Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 38(1):82–89PubMedGoogle Scholar
  91. 91.
    Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS (1998) Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. Am J Gastroenterol 93(11):2154–2161PubMedGoogle Scholar
  92. 92.
    Tsunoda S, Velez R, von Moltke L, Greenblatt D (1999) Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo proble: effect of ketoconazole. Clin Pharmacol Ther 66:461–471PubMedGoogle Scholar
  93. 93.
    Chaobal HN, Kharasch ED (2005) Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin Pharmacol Ther 78(5):529–539PubMedGoogle Scholar
  94. 94.
    Kharasch ED, Walker A, Hoffer C, Sheffels P (2004) Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 76(5):452–466PubMedGoogle Scholar
  95. 95.
    Kharasch ED, Hoffer C, Walker A, Sheffels P (2003) Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin Pharmacol Ther 73(3):199–208PubMedGoogle Scholar
  96. 96.
    Jalava KM, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61(4):410–415PubMedGoogle Scholar
  97. 97.
    von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM et al (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276(2):370–379Google Scholar
  98. 98.
    Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ (2000) Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292(2):618–628PubMedGoogle Scholar
  99. 99.
    Chainuvati S, Nafziger AN, Leeder JS, Gaedigk A, Kearns GL, Sellers E et al (2003) Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the “Cooperstown 5+1 cocktail”. Clin Pharmacol Ther 74(5):437–447PubMedGoogle Scholar
  100. 100.
    Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y et al (2009) Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68(6):928–935PubMedPubMedCentralGoogle Scholar
  101. 101.
    Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot MH, Menez JF (1995) Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 5(2):72–79PubMedGoogle Scholar
  102. 102.
    Backman JT, Granfors MT, Neuvonen PJ (2006) Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62(6):451–461PubMedGoogle Scholar
  103. 103.
    Zhang L, Zhang Y, Zhao P, Huang S-M (2009) Predicting drug-drug interactions: an FDA perspective. AAPS J 11(2):300–306PubMedPubMedCentralGoogle Scholar
  104. 104.
    Backman JT, Filppula AM, Niemi M, Neuvonen PJ (2016) Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev 68(1):168–241PubMedPubMedCentralGoogle Scholar
  105. 105.
    Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ (2005) Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 60(2):208–217PubMedPubMedCentralGoogle Scholar
  106. 106.
    Daily EB, Aquilante CL (2009) Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 10(9):1489–1510PubMedPubMedCentralGoogle Scholar
  107. 107.
    Bruce MA, Hall SD, Haehner-Daniels BD, Gorski JC (2001) In vivo effect of clarithromycin on multiple cytochrome P450s. Drug Metab Dispos 29(7):1023–1028PubMedGoogle Scholar
  108. 108.
    Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F et al (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71(1):89–98PubMedGoogle Scholar
  109. 109.
    Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO et al (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60(5):337–342PubMedGoogle Scholar
  110. 110.
    Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M et al (2004) Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 76(2):113–118PubMedGoogle Scholar
  111. 111.
    Yasar U, Eliasson E, Forslund-Bergengren C, Tybring G, Gadd M, Sjoqvist F et al (2001) The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur J Clin Pharmacol 57(10):729–735PubMedGoogle Scholar
  112. 112.
    Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS (2008) Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab Dispos 36(7):1242–1248PubMedPubMedCentralGoogle Scholar
  113. 113.
    Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML, Llerena A (2003) CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 59(3):221–225PubMedGoogle Scholar
  114. 114.
    Dorado P, Cavaco I, Caceres MC, Piedade R, Ribeiro V, Llerena A (2008) Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 64(10):967–970PubMedGoogle Scholar
  115. 115.
    Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J (2003) Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 55(1):51–61PubMedPubMedCentralGoogle Scholar
  116. 116.
    Hassan-Alin M, Andersson T, Niazi M, Rohss K (2005) A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 60(11):779–784PubMedGoogle Scholar
  117. 117.
    Tybring G, Bottiger Y, Widen J, Bertilsson L (1997) Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 62(2):129–137PubMedGoogle Scholar
  118. 118.
    Masica AL, Mayo G, Wilkinson GR (2004) In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 76(4):341–349PubMedGoogle Scholar
  119. 119.
    Kim JS, Nafziger AN, Tsunoda SM, Choo EE, Streetman DS, Kashuba AD et al (2002) Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J Clin Pharmacol 42(4):376–382PubMedGoogle Scholar
  120. 120.
    Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr (2006) Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 79(4):350–361PubMedGoogle Scholar
  121. 121.
    Kharasch ED, Thummel KE, Watkins PB (2005) CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition. Mol Interv 5(3):151–153PubMedGoogle Scholar
  122. 122.
    Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A et al (2003) The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 73(6):517–528PubMedGoogle Scholar
  123. 123.
    Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L (2003) Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 59(1):23–28PubMedGoogle Scholar
  124. 124.
    Foti RS, Rock DA, Wienkers LC, Wahlstrom JL (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38(6):981–987PubMedGoogle Scholar
  125. 125.
    Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58(5):556–566PubMedGoogle Scholar
  126. 126.
    Gill HJ, Tingle MD, Park BK (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 40(6):531–538PubMedPubMedCentralGoogle Scholar
  127. 127.
    Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG (1998) Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol 54(9-10):741–747PubMedGoogle Scholar
  128. 128.
    Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug “Pittsburgh cocktail” approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 62(4):365–376PubMedGoogle Scholar
  129. 129.
    Sharma A, Pilote S, Belanger PM, Arsenault M, Hamelin BA (2004) A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study. Br J Clin Pharmacol 58(3):288–297PubMedPubMedCentralGoogle Scholar
  130. 130.
    Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJ et al (1999) Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 66(3):224–231PubMedGoogle Scholar
  131. 131.
    Ragueneau-Majlessi I, Boulenc X, Rauch C, Hachad H, Levy RH (2007) Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab 8(8):810–814PubMedGoogle Scholar
  132. 132.
    Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R et al (2005) Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos 33(4):500–507PubMedGoogle Scholar
  133. 133.
    HY K, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK et al (2008) The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos 36(6):986–990Google Scholar
  134. 134.
    Galteau MM, Shamsa F (2003) Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 59(10):713–733PubMedGoogle Scholar
  135. 135.
    Tomalik-Scharte D, Lutjohann D, Doroshyenko O, Frank D, Jetter A, Fuhr U (2009) Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? Clin Pharmacol Ther 86(2):147–153PubMedGoogle Scholar
  136. 136.
    Kasichayanula S, Boulton DW, Luo WL, Rodrigues AD, Yang Z, Goodenough A et al (2014) Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br J Clin Pharmacol 78(5):1122–1134PubMedPubMedCentralGoogle Scholar
  137. 137.
    Bjorkhem-Bergman L, Backstrom T, Nylen H, Ronquist-Nii Y, Bredberg E, Andersson TB et al (2013) Comparison of endogenous 4beta-hydroxycholesterol with midazolam as markers for CYP3A4 induction by rifampicin. Drug Metab Dispos 41(8):1488–1493PubMedGoogle Scholar
  138. 138.
    Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3):243–272PubMedGoogle Scholar
  139. 139.
    Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J et al (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62(1):162–172PubMedGoogle Scholar
  140. 140.
    Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45(1):13–31PubMedGoogle Scholar
  141. 141.
    Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M et al (1999) Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9(3):377–388PubMedGoogle Scholar
  142. 142.
    Girre C, Lucas D, Hispard E, Menez C, Dally S, Menez JF (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47(9):1503–1508PubMedGoogle Scholar
  143. 143.
    Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol 52(5):555–561PubMedPubMedCentralGoogle Scholar
  144. 144.
    Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U (2009) Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected? Eur J Clin Pharmacol 65(4):411–417PubMedGoogle Scholar
  145. 145.
    Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 53(5):503–514PubMedGoogle Scholar
  146. 146.
    Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, Woosley RL et al (1993) Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 3(5):250–255PubMedGoogle Scholar
  147. 147.
    O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ et al (2000) Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 10(2):171–182PubMedGoogle Scholar
  148. 148.
    Luo X, Li XM, ZY H, Cheng ZN (2009) Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism. Acta Pharmacol Sin 30(9):1323–1329PubMedPubMedCentralGoogle Scholar
  149. 149.
    Chen M, Nafziger AN, Bertino JS Jr (2006) Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam. Drug Metab Dispos 34(12):2079–2082PubMedGoogle Scholar
  150. 150.
    Penzak SR, Busse KH, Robertson SM, Formentini E, Alfaro RM, Davey RT Jr (2008) Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions. J Clin Pharmacol 48(6):671–680PubMedPubMedCentralGoogle Scholar
  151. 151.
    Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001) The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70(4):317–326PubMedGoogle Scholar
  152. 152.
    Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, Skott A, Sorgel F, Klaassen T et al (2005) Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 33(12):1859–1866PubMedGoogle Scholar
  153. 153.
    Videau O, Delaforge M, Levi M, Thevenot E, Gal O, Becquemont L et al (2010) Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. Rapid Commun Mass Spectrom 24(16):2407–2419PubMedGoogle Scholar
  154. 154.
    Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A et al (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the “Cooperstown cocktail”. Clin Pharmacol Ther 68(4):375–383PubMedGoogle Scholar
  155. 155.
    Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34(1-2):83–448PubMedGoogle Scholar
  156. 156.
    Shelepova T, Nafziger AN, Victory J, Kashuba AD, Rowland E, Zhang Y et al (2005) Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail. J Clin Pharmacol 45(12):1413–1421PubMedGoogle Scholar
  157. 157.
    Furman KD, Grimm DR, Mueller T, Holley-Shanks RR, Bertz RJ, Williams LA et al (2004) Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 14(5):279–284PubMedGoogle Scholar
  158. 158.
    Kim MJ, Bertino JS Jr, Gaedigk A, Zhang Y, Sellers EM, Nafziger AN (2002) Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin Pharmacol Ther 72(2):192–199PubMedGoogle Scholar
  159. 159.
    Bromley CM, Close S, Cohen N, Favis R, Fijal B, Gheyas F et al (2009) Designing pharmacogenetic projects in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J 9(1):14–22PubMedGoogle Scholar
  160. 160.
    Williams JA, Johnson K, Paulauskis J, Cook J (2006) So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 46(3):258–264PubMedGoogle Scholar
  161. 161.
    Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G et al (2003) Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 13(1):39–47PubMedGoogle Scholar
  162. 162.
    Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lotsch J, Roots I et al (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7(4):257–265PubMedGoogle Scholar
  163. 163.
    Inui N, Akamatsu T, Uchida S, Tanaka S, Namiki N, Karayama M et al (2013) Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. Clin Pharmacol Ther 94(6):702–708PubMedGoogle Scholar
  164. 164.
    De Bock L, Boussery K, Colin P, De Smet J, T'Jollyn H, Van Bocxlaer J (2012) Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. Talanta 89:209–216PubMedGoogle Scholar
  165. 165.
    Scott RJ, Palmer J, Lewis IA, Pleasance S (1999) Determination of a ‘GW cocktail’ of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 13(23):2305–2319PubMedGoogle Scholar
  166. 166.
    Statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, 2001Google Scholar
  167. 167.
    Group Mr. Drug interaction guideline for drug development and labeling recommendations (draft for public comment). Japan: Ministry of Health, Labour and Welfare, 2014, pp 75–76Google Scholar
  168. 168.
    Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR et al (2001) In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11(9):781–791PubMedGoogle Scholar
  169. 169.
    Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA et al (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci U S A 82(18):6310–6314PubMedPubMedCentralGoogle Scholar
  170. 170.
    Kronbach T, Fischer V, Meyer UA (1988) Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 43(6):630–635PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Bertino ConsultingSchenectadyUSA
  2. 2.School of Pharmacy & Pharmaceutical Sciences, Department of Pharmacy PracticeUniversity at Buffalo, State University of New YorkBuffaloUSA
  3. 3.College of Physicians & SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations